IL-17RA blockade by brodalumab hidradenitis suppurativa

The goal of this study is to characterize the molecular response of HS patients to brodalumab therapy in skin and serum, and to identify biomarkers of treatment response. Ten participants that received 210 mg/1.5mL brodalumab subcutaneously at week 0, 1, 2, 4 and every 2 weeks after were included in this molecular profiling study (NCT03960268). RNA-sequencing of nonlesional, perilesional and lesional HS skin biopsies was assessed. Overall design: Punch biopsies of nonlesional, perilesional and lesional HS skin were collected under ultrasound guidance as part of NCT03960268. Biopsies were collected prior to treatment (baseline) and at week 12, with an optional week 4 biopsy.